ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Last trade$3.70
Day change+$0.11 (+3.06%)
Day range$3.51 – $3.78
Volume721,975
Market cap$361M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$360.9M
Price / earnings
—
Price / book
-30.19×
Price / sales
2.95×
EV / sales
4.36×
EV / EBITDA
-2.72×
Profitability
Earnings per share
-$1.99
Return on assets
-79.39%
Return on equity
1,669.94%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-16.48×
Current ratio
3.25×
Quick ratio
3.07×
Cash ratio
0.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$183.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SPRY, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$37.71M
$33.66M
$22.68M
$28.09M
$32.5M
$15.72M
$7.97M
$86.58M
Cost of revenue
$10.1M
$12.85M
$6.29M
$6.15M
$8.19M
$4.98M
$1.09M
$865K
Gross profit
$27.61M
$20.81M
$16.4M
$21.93M
$24.31M
$10.73M
$6.88M
$85.72M
Selling, general and administrative
$43.52M
$77.58M
$72.2M
$59.96M
$74.75M
$54.31M
$41.1M
$35.49M
Research and development
$18.26M
$4.7M
$4.34M
$3.44M
$2.75M
$4.04M
$2.95M
$3.03M
Total operating expenses
$61.78M
$82.28M
$76.54M
$63.4M
$77.5M
$58.35M
$44.06M
$38.52M
Operating income
-$34.17M
-$61.47M
-$60.15M
-$41.47M
-$53.19M
-$47.61M
-$37.18M
$47.2M
Interest expense
-$2.55M
-$2.48M
$0
$0
-$56K
$0
$0
$0
Income before taxes
-$35.59M
-$62.34M
-$60.62M
-$41.18M
-$51.15M
-$44.88M
-$33.94M
$49.93M
Income taxes
$0
$0
$0
-$80K
$0
$0
$0
$288K
Net income
-$35.59M
-$62.34M
-$60.62M
-$41.1M
-$51.15M
-$44.88M
-$33.94M
$49.64M
Net income attributable to common shareholders
-$35.59M
-$62.34M
-$60.62M
-$41.1M
-$51.15M
-$44.88M
-$33.94M
$49.64M
EBITDA
-$33.76M
-$61.05M
-$59.75M
-$41.05M
-$52.8M
-$47.34M
-$36.9M
$47.23M
Basic earnings per share
-$0.36
-$0.63
-$0.61
-$0.41
-$0.52
-$0.46
-$0.35
$0.51
Diluted earnings per share
-$0.36
-$0.63
-$0.61
-$0.41
-$0.52
-$0.46
-$0.35
$0.42
Recent news
Company coverage with links to the original publishers.
ARS Pharmaceuticals reported a Q3 loss of $0.36 per share, missing consensus estimates of $0.34 loss, and posted revenues of $37.71 million, falling 11.66% short of expectations. The stock has declined 73.8% year-to-date and received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.
ARS Pharmaceuticals (SPRY) is expected to report a quarterly loss of $0.34 per share with revenues of $42.69 million on November 5, 2026. The company has a negative Earnings ESP of -19.40% and Zacks Rank #4, making it unlikely to beat consensus estimates. SPRY has missed EPS estimates in all of the last four quarters.
A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.
A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales.
A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.